- Home
- APM vs SNOA Comparison
APM vs SNOA Comparison
Compare APM & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- SNOA
- Stock Information
- Founded
- APM 2010
- SNOA 1999
- Country
- APM United Kingdom
- SNOA United States
- Employees
- APM N/A
- SNOA N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- SNOA Health Care
- Exchange
- APM Nasdaq
- SNOA Nasdaq
- Market Cap
- APM 6.1M
- SNOA 6.4M
- IPO Year
- APM 2018
- SNOA 2007
- Fundamental
- Price
- APM $1.07
- SNOA $3.32
- Analyst Decision
- APM
- SNOA
- Analyst Count
- APM 0
- SNOA 0
- Target Price
- APM N/A
- SNOA N/A
- AVG Volume (30 Days)
- APM 81.2K
- SNOA 60.2K
- Earning Date
- APM 06-17-2025
- SNOA 06-16-2025
- Dividend Yield
- APM N/A
- SNOA N/A
- EPS Growth
- APM N/A
- SNOA N/A
- EPS
- APM N/A
- SNOA N/A
- Revenue
- APM N/A
- SNOA $13,973,000.00
- Revenue This Year
- APM N/A
- SNOA $23.89
- Revenue Next Year
- APM N/A
- SNOA $25.45
- P/E Ratio
- APM N/A
- SNOA N/A
- Revenue Growth
- APM N/A
- SNOA 13.51
- 52 Week Low
- APM $0.46
- SNOA $1.75
- 52 Week High
- APM $7.49
- SNOA $9.37
- Technical
- Relative Strength Index (RSI)
- APM 58.89
- SNOA 52.15
- Support Level
- APM $0.83
- SNOA $3.05
- Resistance Level
- APM $1.35
- SNOA $3.60
- Average True Range (ATR)
- APM 0.12
- SNOA 0.19
- MACD
- APM 0.02
- SNOA -0.01
- Stochastic Oscillator
- APM 46.97
- SNOA 49.09
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.